[go: up one dir, main page]

AU2001295531A1 - Antisense oligonucleotides against vanilloid receptor 1 - Google Patents

Antisense oligonucleotides against vanilloid receptor 1

Info

Publication number
AU2001295531A1
AU2001295531A1 AU2001295531A AU9553101A AU2001295531A1 AU 2001295531 A1 AU2001295531 A1 AU 2001295531A1 AU 2001295531 A AU2001295531 A AU 2001295531A AU 9553101 A AU9553101 A AU 9553101A AU 2001295531 A1 AU2001295531 A1 AU 2001295531A1
Authority
AU
Australia
Prior art keywords
antisense oligonucleotides
vanilloid receptor
oligonucleotides against
against vanilloid
nucleotide constructs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001295531A
Inventor
Volker A. Erdmann
Jens Kurreck
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gruenenthal GmbH
Original Assignee
Gruenenthal GmbH
Chemie Gruenenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE2000143674 external-priority patent/DE10043674A1/en
Priority claimed from DE10043702A external-priority patent/DE10043702A1/en
Application filed by Gruenenthal GmbH, Chemie Gruenenthal GmbH filed Critical Gruenenthal GmbH
Publication of AU2001295531A1 publication Critical patent/AU2001295531A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/121—Hammerhead
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Antisense oligodeoxynucleotides against VR1, corresponding nucleotide constructs, cells containing said nucleotide constructs, pharmaceutical and diagnostic substances, uses thereof in pain therapy, and methods for diagnosing symptoms related to VR1 and for identifying pain-modulating substances.
AU2001295531A 2000-09-02 2001-08-31 Antisense oligonucleotides against vanilloid receptor 1 Abandoned AU2001295531A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE2000143674 DE10043674A1 (en) 2000-09-02 2000-09-02 New antisense oligonucleotides and ribozymes, useful for treating e.g. pain and for diagnosis, are directed against mRNA for vanilloid-family receptors
DE10043674.9 2000-09-02
DE10043702.8 2000-09-04
DE10043702A DE10043702A1 (en) 2000-09-04 2000-09-04 New antisense oligonucleotides and ribozymes, useful for treating e.g. pain and for diagnosis, are directed against mRNA for vanilloid-family receptors
PCT/EP2001/010081 WO2002018407A2 (en) 2000-09-02 2001-08-31 Antisense oligonucleotides against vanilloid receptor 1

Publications (1)

Publication Number Publication Date
AU2001295531A1 true AU2001295531A1 (en) 2002-03-13

Family

ID=26006931

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001295531A Abandoned AU2001295531A1 (en) 2000-09-02 2001-08-31 Antisense oligonucleotides against vanilloid receptor 1

Country Status (13)

Country Link
US (2) US7662948B2 (en)
EP (1) EP1313768B1 (en)
JP (1) JP2004507263A (en)
AT (1) ATE385505T1 (en)
AU (1) AU2001295531A1 (en)
CA (1) CA2420656A1 (en)
DE (1) DE50113568D1 (en)
ES (1) ES2300366T3 (en)
HU (1) HUP0301805A3 (en)
MX (1) MXPA03001627A (en)
NZ (1) NZ524894A (en)
PL (1) PL366039A1 (en)
WO (1) WO2002018407A2 (en)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030105044A1 (en) * 2001-10-17 2003-06-05 Isis Pharmaceuticals Inc. Antisense modulation of matrix metalloproteinase 1 expression
DK2264172T3 (en) 2002-04-05 2017-11-27 Roche Innovation Ct Copenhagen As Oligomeric Compounds for Modulating HIF-1α Expression
DE10322662A1 (en) * 2002-11-06 2004-10-07 Grünenthal GmbH New DNA type 10-23 enzyme, useful for treating e.g. pain, and related short interfering RNA, directed against the vanillin receptor or picorna viruses, contains specific nucleotide modifications for improved stability
DE10257421A1 (en) * 2002-12-09 2004-07-08 Grünenthal GmbH Regulatory elements in the 5 'region of the VR1 gene
US20040115634A1 (en) * 2002-12-11 2004-06-17 Isis Pharmaceuticals, Inc. Modulation of stat 6 expression
US7480382B2 (en) * 2003-09-30 2009-01-20 Microsoft Corporation Image file container
NZ555644A (en) * 2004-11-09 2009-04-30 Santaris Pharma As Potent LNA oligonucleotides for the inhibition of HIF-1A expression
US9447138B2 (en) 2004-11-09 2016-09-20 Roche Innovation Center Copenhagen A/S Potent LNA oligonucleotides for the inhibition of HIF-1a expression
CN101437933B (en) 2005-12-28 2013-11-06 斯克里普斯研究所 Natural antisense and non-coding RNA transcripts as drug targets
RU2604489C2 (en) * 2008-10-03 2016-12-10 КьюРНА,Инк.,US Treatment of apolipoprotein-a1 related diseases by inhibition of natural antisense transcript to apolipoprotein-a1
CN102341498B (en) 2008-12-04 2017-12-19 库尔纳公司 Natural antisense transcripton by suppressing VEGF (VEGF) treats the related diseases of VEGF
RU2746478C2 (en) 2008-12-04 2021-04-14 КьюРНА, Инк. Treatment of tumors of diseases related to the genom-suppressor by therapy of natural transcript inhibition in anti-significant orientation regarding this gene
KR101829469B1 (en) 2008-12-04 2018-03-30 큐알엔에이, 인크. Treatment of erythropoietin (epo) related diseases by inhibition of natural antisense transcript to epo
EP2396038B1 (en) 2009-02-12 2015-10-21 CuRNA, Inc. Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
EP2408919B1 (en) 2009-03-16 2017-10-18 CuRNA, Inc. Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2
ES2627763T3 (en) 2009-03-17 2017-07-31 Curna, Inc. Treatment of diseases related to the delta 1 homologue (dlk1) by inhibition of natural antisense transcript to dlk1
WO2010129746A2 (en) 2009-05-06 2010-11-11 Curna, Inc. Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp
CN102459596B (en) 2009-05-06 2016-09-07 库尔纳公司 Treatment of Lipid Transport and Metabolism Gene-Associated Diseases by Inhibition of Natural Antisense Transcripts Targeting Lipid Transport and Metabolism Genes
KR101742334B1 (en) 2009-05-08 2017-06-01 큐알엔에이, 인크. Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to dmd family
DK2432881T3 (en) 2009-05-18 2018-02-26 Curna Inc TREATMENT OF REPROGRAMMING FACTOR-RELATED DISEASES BY INHIBITING NATURAL ANTISENSE TRANSCRIPTS TO A REPROGRAMMING FACTOR
KR101703695B1 (en) 2009-05-22 2017-02-08 큐알엔에이, 인크. Treatment of transcription factor e3 (tfe3) and insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to tfe3
ES2618576T3 (en) 2009-05-28 2017-06-21 Curna, Inc. Treatment of diseases related to an antiviral gene by inhibiting a natural antisense transcript to an antiviral gene
CA2765509C (en) 2009-06-16 2021-08-17 Joseph Collard Treatment of paraoxonase 1 (pon1) related diseases by inhibition of natural antisense transcript to pon1
JP5944311B2 (en) 2009-06-16 2016-07-05 クルナ・インコーポレーテッド Treatment of collagen gene-related diseases by suppression of natural antisense transcripts against collagen genes
KR101807323B1 (en) 2009-06-24 2017-12-08 큐알엔에이, 인크. Ttreatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2
US8921330B2 (en) 2009-06-26 2014-12-30 Curna, Inc. Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene
CN102712925B (en) 2009-07-24 2017-10-27 库尔纳公司 Treatment of SIRTUIN (SIRT)-associated diseases by inhibiting the natural antisense transcript of SIRTUIN (SIRT)
US8572084B2 (en) * 2009-07-28 2013-10-29 Fti Consulting, Inc. System and method for displaying relationships between electronically stored information to provide classification suggestions via nearest neighbor
WO2011017516A2 (en) 2009-08-05 2011-02-10 Curna, Inc. Treatment of insulin gene (ins) related diseases by inhibition of natural antisense transcript to an insulin gene (ins)
US9044493B2 (en) 2009-08-11 2015-06-02 Curna, Inc. Treatment of Adiponectin related diseases by inhibition of natural antisense transcript to an Adiponectin
JP5943836B2 (en) 2009-08-21 2016-07-05 カッパーアールエヌエー，インコーポレイテッド Treatment of CHIP-related diseases by inhibition of natural antisense transcripts on 'HSP70 interacting protein C-terminus' (CHIP)
WO2011031482A2 (en) 2009-08-25 2011-03-17 Curna, Inc. Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap
KR101802540B1 (en) 2009-09-25 2017-11-28 큐알엔에이, 인크. Treatment of filaggrin (flg) related diseases by modulation of flg expression and activity
ES2661813T3 (en) 2009-12-16 2018-04-04 Curna, Inc. Treatment of diseases related to membrane transcription factor peptidase, site 1 (mbtps1) by inhibition of the natural antisense transcript to the mbtps1 gene
CN102869776B (en) 2009-12-23 2017-06-23 库尔纳公司 HGF relevant diseases are treated by suppressing the natural antisense transcript of HGF (HGF)
US9068183B2 (en) 2009-12-23 2015-06-30 Curna, Inc. Treatment of uncoupling protein 2 (UCP2) related diseases by inhibition of natural antisense transcript to UCP2
JP5982288B2 (en) 2009-12-29 2016-08-31 カッパーアールエヌエー，インコーポレイテッド Treatment of tumor protein 63-related diseases by inhibition of natural antisense transcripts against tumor protein 63 (p63)
EP2519633B1 (en) 2009-12-29 2017-10-25 CuRNA, Inc. Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1
WO2011082281A2 (en) 2009-12-31 2011-07-07 Curna, Inc. Treatment of insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to irs2 and transcription factor e3 (tfe3)
KR101878501B1 (en) 2010-01-04 2018-08-07 큐알엔에이, 인크. Treatment of interferon regulatory factor 8 (irf8) related diseases by inhibition of natural antisense transcript to irf8
WO2011085066A2 (en) 2010-01-06 2011-07-14 Curna, Inc. Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene
CN102803493B (en) 2010-01-11 2018-07-31 库尔纳公司 SHBG relevant diseases are treated by inhibiting the natural antisense transcript of sex hormone binding globulin (SHBG)
KR101853510B1 (en) 2010-01-25 2018-06-20 큐알엔에이, 인크. Treatment of rnase h1 related diseases by inhibition of natural antisense transcript to rnase h1
CA2790506A1 (en) 2010-02-22 2011-08-25 Curna, Inc. Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1
CN102869777B (en) 2010-04-02 2018-11-02 库尔纳公司 CSF3 relevant diseases are treated by inhibiting the natural antisense transcript of colony stimulating factor 3 (CSF3)
EP2556160A4 (en) 2010-04-09 2013-08-21 Curna Inc Treatment of fibroblast growth factor 21 (fgf21) related diseases by inhibition of natural antisense transcript to fgf21
WO2011139387A1 (en) 2010-05-03 2011-11-10 Opko Curna, Llc Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
TWI586356B (en) 2010-05-14 2017-06-11 可娜公司 Treatment of par4 related diseases by inhibition of natural antisense transcript to par4
CA2799596C (en) 2010-05-26 2020-09-22 Curna, Inc. Treatment of methionine sulfoxide reductase a (msra) related diseases by inhibition of natural antisense transcript to msra
KR101857090B1 (en) 2010-05-26 2018-06-26 큐알엔에이, 인크. Treatment of atonal homolog 1 (atoh1) related diseases by inhibition of natural antisense transcript to atoh1
CN103025873B (en) 2010-06-23 2018-05-08 库尔纳公司 Treatment of SCNA-associated diseases by inhibiting natural antisense transcripts of voltage-gated sodium channel alpha subunit (SCNA)
RU2611190C2 (en) 2010-07-14 2017-02-21 Курна, Инк. Treatment of diseases related with gene dlg by inhibition of natural antisense transcript of dlg gene
CA2813901C (en) 2010-10-06 2019-11-12 Curna, Inc. Treatment of sialidase 4 (neu4) related diseases by inhibition of natural antisense transcript to neu4
EP2630241B1 (en) 2010-10-22 2018-10-17 CuRNA, Inc. Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua
US10000752B2 (en) 2010-11-18 2018-06-19 Curna, Inc. Antagonat compositions and methods of use
RU2608493C2 (en) 2010-11-23 2017-01-18 Курна, Инк. Treating diseases, associated with nanog, by inhibition of natural antisense nanog transcript
US9593330B2 (en) 2011-06-09 2017-03-14 Curna, Inc. Treatment of frataxin (FXN) related diseases by inhibition of natural antisense transcript to FXN
US10583128B2 (en) 2011-09-06 2020-03-10 Curna, Inc. Treatment of diseases related to alpha subunits of sodium channels, voltage-gated (SCNxA) with small molecules
ES2694592T3 (en) 2012-03-15 2018-12-21 Curna, Inc. Treatment of diseases related to brain-derived neurotrophic factor (BDNF) by inhibition of the natural antisense transcript of BDNF
CA2941903A1 (en) 2014-04-01 2015-10-08 Koti Tatachar Sreekrishna Method for screening trp channels
GB201410693D0 (en) 2014-06-16 2014-07-30 Univ Southampton Splicing modulation
SG11201702682PA (en) 2014-10-03 2017-04-27 Cold Spring Harbor Lab Targeted augmentation of nuclear gene output
US10196639B2 (en) 2015-10-09 2019-02-05 University Of Southampton Modulation of gene expression and screening for deregulated protein expression
JP7049248B2 (en) 2015-12-14 2022-04-06 コールド スプリング ハーバー ラボラトリー Autosomal dominant mental retardation-5 and antisense oligomers for the treatment of Dravet syndrome
US11096956B2 (en) 2015-12-14 2021-08-24 Stoke Therapeutics, Inc. Antisense oligomers and uses thereof
WO2018081189A1 (en) 2016-10-25 2018-05-03 The Procter & Gamble Company Fibrous structures
CA3037094C (en) 2016-10-25 2021-12-28 The Procter & Gamble Company Fibrous structures
KR102318434B1 (en) 2017-08-25 2021-11-01 스톡 테라퓨틱스, 인크. Antisense oligomers for the treatment of conditions and diseases
US12060558B2 (en) 2018-05-04 2024-08-13 Stoke Therapeutics, Inc. Methods and compositions for treatment of cholesteryl ester storage disease
IL298063A (en) 2020-05-11 2023-01-01 Stoke Therapeutics Inc Opa1 antisense oligomers for treatment of conditions and diseases

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6278038B1 (en) * 1992-04-10 2001-08-21 Oregon Health And Science University Mammalian melanocortin receptors and uses
US5985558A (en) * 1997-04-14 1999-11-16 Isis Pharmaceuticals Inc. Antisense oligonucleotide compositions and methods for the inibition of c-Jun and c-Fos
FR2724934B1 (en) * 1994-09-26 1997-01-24 Bio Merieux CHIMERIC OLIGONUCLEOTIDE AND ITS USE IN OBTAINING NUCLEIC ACID TRANSCRIPTS
US6346398B1 (en) * 1995-10-26 2002-02-12 Ribozyme Pharmaceuticals, Inc. Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
AU742391B2 (en) * 1997-08-20 2002-01-03 Regents Of The University Of California, The Nucleic acid sequences encoding capsaicin receptor and capsaicin receptor-related polypeptides and uses thereof
CA2309903C (en) * 1998-01-22 2012-03-27 The Regents Of The University Of California Nucleic acid sequences encoding capsaicin receptor
EP0943683A1 (en) 1998-03-10 1999-09-22 Smithkline Beecham Plc Human vanilloid receptor homologue Vanilrep1
GB9822124D0 (en) * 1998-10-09 1998-12-02 Univ London Ion channels
CA2348479A1 (en) * 1998-11-13 2000-05-25 Millennium Pharmaceuticals, Inc. Novel members of the capsaicin/vanilloid receptor family of proteins and uses thereof
GB9826359D0 (en) 1998-12-01 1999-01-27 Glaxo Group Ltd Novel receptors
GB9827016D0 (en) 1998-12-08 1999-02-03 Merck Sharp & Dohme Receptor protein
EP1175504A4 (en) 1999-04-15 2002-07-31 Ortho Mcneil Pharm Inc Dna encoding the human vanilloid receptor vr1
US6482611B1 (en) * 1999-09-23 2002-11-19 Neurogen Corporation Human capsaicin receptor and uses thereof
US20040259092A1 (en) * 2001-08-27 2004-12-23 Carmen Barske Nogo receptor homologues and their use

Also Published As

Publication number Publication date
ES2300366T3 (en) 2008-06-16
EP1313768A2 (en) 2003-05-28
NZ524894A (en) 2005-03-24
HUP0301805A3 (en) 2005-12-28
US7662948B2 (en) 2010-02-16
WO2002018407A3 (en) 2002-10-03
HUP0301805A2 (en) 2003-08-28
US20100316615A1 (en) 2010-12-16
WO2002018407A9 (en) 2003-05-15
MXPA03001627A (en) 2003-06-24
JP2004507263A (en) 2004-03-11
US20040002473A1 (en) 2004-01-01
CA2420656A1 (en) 2003-02-26
EP1313768B1 (en) 2008-02-06
WO2002018407A2 (en) 2002-03-07
PL366039A1 (en) 2005-01-24
ATE385505T1 (en) 2008-02-15
DE50113568D1 (en) 2008-03-20

Similar Documents

Publication Publication Date Title
AU2001295531A1 (en) Antisense oligonucleotides against vanilloid receptor 1
CA2296535A1 (en) Antisense oligonucleotide inhibition of ras
EP1340765A3 (en) Inverted chimeric and hybrid oligonucleotides
DE69835201D1 (en) Neoglycoproteine
MXPA03002413A (en) B7-like molecules and uses thereof.
WO2001048190A3 (en) Therapeutic uses of lna-modified oligonucleotides
WO1998050547A3 (en) Human toll-like receptor proteins, related reagents and methods
CA2194761A1 (en) Immunomodulatory oligonucleotides
MXPA02011656A (en) Nrg 2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods.
FR2722506B1 (en) COMPOSITION CONTAINING NUCLEIC ACIDS, PREPARATION AND USES
AP9901654A0 (en) Gene sequencer and methods.
ATE202569T1 (en) PRODRUG OLIGONUCLEOTIDES
AU8881201A (en) Tnf receptor-like molecules and uses thereof
WO2002012338A3 (en) Screening method
GR3034534T3 (en) Novel polymer supports for nucleic acid synthesis
DE60134645D1 (en) AMIDINE DERIVATIVES AS SELECTIVE NMDA RECEPTOR ANTAGONISTS
CA2495298A1 (en) Use of antisense oligonucleotides to inhibit the expression of akt-1
WO2004013313A3 (en) Antisense nucleic acids
ZA984838B (en) Bacterial pheromones and uses therefor.
AU2001244354A1 (en) Retinoic acid receptor beta-2, its antagonists, and gene therapy vectors for thetreatment of neurological disorders
WO2005035549A3 (en) Amiphiphylic peptide-pna conjugates for the delivery of pna through the blood brain barrier
AU2347501A (en) Trp-protein-related mtr1 protein and dna sequence coding therefor
AU2739797A (en) (in situ) preparation of nucleoside phosphoramidites and their use in synthesis of oligonucleotides
WO2004108898A3 (en) Transfection agents
EP0914324A2 (en) Specific inhibitors of dna methyltransferase enzyme

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application